2.15
price down icon2.27%   -0.05
after-market Handel nachbörslich: 2.16 0.01 +0.47%
loading
Schlusskurs vom Vortag:
$2.20
Offen:
$2.2
24-Stunden-Volumen:
126.02K
Relative Volume:
0.46
Marktkapitalisierung:
$7.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.47M
KGV:
-4.30
EPS:
-0.5
Netto-Cashflow:
$-13.51M
1W Leistung:
-2.17%
1M Leistung:
-10.79%
6M Leistung:
+13.76%
1J Leistung:
-70.17%
1-Tages-Spanne:
Value
$2.10
$2.22
1-Wochen-Bereich:
Value
$2.10
$2.35
52-Wochen-Spanne:
Value
$1.30
$15.59

Nls Pharmaceutics Ltd Stock (NLSP) Company Profile

Name
Firmenname
Nls Pharmaceutics Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
1
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
NLSP's Discussions on Twitter

Vergleichen Sie NLSP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NLSP
Nls Pharmaceutics Ltd
2.15 10.79M 0 -15.47M -13.51M -0.50
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Nls Pharmaceutics Ltd Aktie (NLSP) Neueste Nachrichten

pulisher
Jul 22, 2025

Is NLS Pharmaceutics AG a good long term investmentConsistently high returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Is NLS Pharmaceutics AG Equity Warrant a good long term investmentPhenomenal capital gains - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

What analysts say about NLS Pharmaceutics AG Equity Warrant stockFree Consultation - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

What risks could impact NLS Pharmaceutics AG Equity Warrant stock performanceMassive Upside Selection - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

How NLS Pharmaceutics AG stock reacts to Fed policy changesCapital Protected Stock Selections - Newser

Jul 17, 2025
pulisher
Jul 17, 2025

NLS Pharma's Diabetes Treatment Project Gets Fresh Funding Boost From US-Israel Foundation - 富途牛牛

Jul 17, 2025
pulisher
Jul 17, 2025

NLS Pharmaceutics Advances iTOL-102 Diabetes Program with BIRD Foundation Support - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Bird Foundation Approves Additional Milestone Payment to Kadimastem and Itolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - MarketScreener

Jul 17, 2025
pulisher
Jul 17, 2025

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - PR Newswire

Jul 17, 2025
pulisher
Jul 15, 2025

Why NLS Pharmaceutics AG Equity Warrant stock attracts strong analyst attentionFree Smart Money Stock Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How NLS Pharmaceutics AG stock performs during market volatilityRapid Gain Targets - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes NLS Pharmaceutics AG stock price move sharplyHigh Confidence Trade Setups - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes NLS Pharmaceutics AG Equity Warrant stock price move sharplyElite Stock Shortlist - Newser

Jul 15, 2025
pulisher
Jul 05, 2025

NLS Pharmaceutics (NASDAQ:NLSP) Upgraded at Wall Street Zen - Defense World

Jul 05, 2025
pulisher
Jul 03, 2025

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - Newswire :) Press Release Distribution

Jul 03, 2025
pulisher
Jul 02, 2025

NLS Pharmaceutics Gains Shareholder Approval for Strategic Agenda - The Globe and Mail

Jul 02, 2025
pulisher
Jul 01, 2025

AGCO nets $260M from TAFE buyback; standstill caps 16% stake | NLSPW SEC FilingForm 6-K - Stock Titan

Jul 01, 2025
pulisher
Jun 30, 2025

NLS Pharmaceutics and Kadimastem Closes $1 Million Equity Financing - citybiz

Jun 30, 2025
pulisher
Jun 30, 2025

NLS Pharmaceutics Secures $1 Million Through Equity Financing Amendment - TipRanks

Jun 30, 2025
pulisher
Jun 30, 2025

NLS Pharmaceutics Soars 10.04% Pre-Market on Investor Optimism - AInvest

Jun 30, 2025
pulisher
Jun 30, 2025

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing - PR Newswire

Jun 30, 2025
pulisher
Jun 30, 2025

MIRA Pharma’s SKNY-1 cuts weight 30% & curbs cravings in animal study | NLSPW SEC FilingForm 6-K - Stock Titan

Jun 30, 2025
pulisher
Jun 16, 2025

NLS Pharmaceutics Announces Strategic Merger and Financing Milestones - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

NLS Pharmaceutics CEO Issues Letter to Shareholders - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

NLS Pharmaceutics Transforms: $25M Backing Powers Merger Deal as Company Goes Debt-Free - Stock Titan

Jun 16, 2025
pulisher
Jun 10, 2025

NLS Pharmaceutics Announces June 2025 Shareholders’ Meeting Amid Financial Losses - TipRanks

Jun 10, 2025
pulisher
May 30, 2025

Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Decreases By 56.6% - Defense World

May 30, 2025
pulisher
May 21, 2025

NLS Pharmaceutics to present Mazindol study at ASCP Meeting By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

NLS Pharmaceutics to present Mazindol study at ASCP Meeting - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

NLS Pharmaceutics (NLSP) to Showcase Promising Data on Mazindol ER | NLSP Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Ma - GuruFocus

May 21, 2025
pulisher
May 21, 2025

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting - Nasdaq

May 21, 2025
pulisher
May 14, 2025

NLS Pharmaceutics (NASDAQ:NLSP) Trading Down 0.6% – Should You Sell? - Defense World

May 14, 2025
pulisher
May 05, 2025

NLS Pharmaceutics Extends Merger Agreement with Kadimastem - TipRanks

May 05, 2025
pulisher
May 03, 2025

NLSPNls Pharmaceutics Ltd Latest Stock News & Market Updates - Stock Titan

May 03, 2025
pulisher
May 01, 2025

NLS Pharmaceutics Delays Yearly Report Filing - TipRanks

May 01, 2025
pulisher
Apr 26, 2025

NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 25, 2025

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 25, 2025

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

NLS Pharmaceutics Announces Board Resignation Amid Restructuring Efforts - TipRanks

Apr 24, 2025
pulisher
Apr 18, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 18, 2025

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 16, 2025

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

Apr 16, 2025
pulisher
Apr 15, 2025

NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

NLS Pharmaceutics (NLSP): Promising Preclinical Results for Mazi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - Quantisnow

Apr 15, 2025

Finanzdaten der Nls Pharmaceutics Ltd-Aktie (NLSP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):